key: cord-0043001-6b704ry8
authors: Abreu, Maria T; Okada, Lauren; Dervieux, Thierry; Luo, Allison; Jain, Anjali; Ritter, Timothy; Hanauer, Stephen B
title: Use of the Endoscopic Healing Index (EHI) for Monitoring of Disease Activity in Crohn’s Disease Patients in the COVID Era
date: 2020-05-02
journal: Crohns Colitis 360
DOI: 10.1093/crocol/otaa035
sha: e0d37eac35be2bf30620fa6de5fe01f6dfb5445d
doc_id: 43001
cord_uid: 6b704ry8

Management of Crohn’s disease (CD) during COVID-19 is challenging when colonoscopy is not feasible. This study describes a blood-based test that has been validated against colonoscopy in CD patients as an alternative even in patients with high inflammation from infections.

As physicians caring for Crohn's patients during the COVID-19 epidemic, we are looking for ways to non-invasively follow patients. Even stool collection has been an issue with the concern of the virus shed in stool. That was the impetus for the attached in silico study. We tested the hypothesis that the EHI would continue to be of value for physicians and patients in the face of elevated CRP driven by infection. Our results demonstrate that indeed the EHI is largely unchanged. Although ideally we would test actual patient samples with high CRP, these data provide reassurance that EHI can be used to examine active Crohn's disease and make clinical decisions.

We thank you for consideration of this brief communication, and we look forward to your response. In the absence of universal COVID testing, use of CRP as a biomarker for the assessment of disease activity in patients with Crohn's disease (CD) who may also be infected with COVID could be inaccurate. Measuring fecal calprotectin may also pose safety concerns associated with collection and handling of fecal material, which has a high SARS-CoV-2 viral RNA concentration 6 .

The Endoscopic Healing Index (EHI, Monitr TM ), a serum test that combines 13 protein biomarkers to produce a quantitative EHI score (range 0-100), was developed and validated against colonoscopy in CD patients 7 . At a cutoff <20, EHI yields an 83.2% sensitivity to rule out endoscopically active disease; while a cutoff >50 yields an 87.8% specificity to rule in endoscopically active disease. We tested the hypothesis that varying the levels of CRP, one of the proteins measured in the EHI assay, would not significantly change the proportion of CD patients identified as having active disease.

To test this hypothesis, we performed an in silico experiment to assess the impact of isolated CRP elevation on EHI score and its categorical assignment. The percentage of specimens in the clinically relevant groups of EHI<20, EHI 20-50 and EHI>50 were 33.2% (N=2,732), 59.2% (N=4,876), and 7.6% (N=630), respectively. Median change in EHI score in specimens within the original EHI<20 group varied from 1 to 3 EHI units when CRP concentrations were increased from 10 mg/L to 60 mg/L ( Figure 1 ). The impact of increasing CRP levels on EHI categorical assignment (Table 1) revealed that 84.6% specimens presenting with EHI <20 remained within that group in the presence of several fold increased CRP to 10 mg/L (median increase: 2 EHI units, IQR: [1] [2] [3] ). Very large increase in CRP (to 60 mg/L) resulted in 31.8% specimens changing EHI assignment from <20 to ≥20 but even this large increase in CRP concentration did not result in EHI >50.

Shelter at home and social distancing have been the primary measures used to control the spread of COVID-19. Most elective endoscopic procedures have been stopped as part of this effort. There is an urgent unmet need for safe and accurate non-invasive alternatives to endoscopy for assessing objective disease measure in patients with CD. Because CRP is a systemic inflammatory biomarker, it may not be reliable for measuring disease activity of CD in patients who may also have COVID-19 infection. In particular, gastrointestinal symptoms frequently occur with COVID-19 and may lead to confusion about IBD flare versus COVID-19 8-10 .

Our simulation data from 8,238 patient specimens demonstrate that EHI scores remain relatively stable despite increased CRP concentrations, thus suggesting that even though CRP is one of the 13 M a n u s c r i p t M a n u s c r i p t 

Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period

Laboratory Parameters in Detection of COVID-19 Patients with Positive RT-PCR; a Diagnostic Accuracy Study

C-reactive protein correlates with CT findings and predicts severe COVID-19 early

Clinical Characteristics of Coronavirus Disease 2019 in China

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

Virological assessment of hospitalized patients with COVID-2019

Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission

Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis

A c c e p t e d M a n u s c r i p t 6 markers within EHI, an isolated increase in CRP does not significantly impact the score or its clinical interpretation. Results from this simulation exercise are not unexpected as the biomarkers within the EHI algorithm are weighted i.e., contribution of each biomarker to the algorithm is different. Therefore, the algorithm is not dependent on any one biomarker such as CRP but the EHI score is the result of all 13 biomarkers. In summary, EHI is potentially a reliable and robust alternative for the non-invasive assessment of objective disease activity in CD patients.A c c e p t e d M a n u s c r i p t 7